Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals

In 2000, NIDA created the Clinical Trials Network (CTN). The CTN conducts studies of behavioral, pharmacological and integrated behavioral and pharmacological treatment interventions in
rigorous, multi-site clinical trials to determine the effectiveness across a broad range of community-based
treatment settings and diverse patient populations. In 2002, tablet formulations of buprenorphine were approved by the FDA for treatment of opiate addiction. Additionally, the CTN completed several clinical trials related to specific uses of this medication. Information from these studies is incorporated into this
training material. In order to prepare the field to effectively integrate this treatment, NIDA formed
a Blending Team to develop an awareness training for multidisciplinary addiction professionals to
educate them about buprenorphine and its use in the treatment of opioid addiction.

This training is designed to provide a broad overview of the medication, its effects, and the roles of multidisciplinary addiction professionals in providing and supporting the treatment of individuals receiving this medication.

Participants will:

• Identify groups of people using opioids

• Describe and define opioid agonists, partial agonists and antagonists

• Identify uses of buprenorphine in opioid treatment

• Define components of patient selection processes

• Identify key issues in coordinating care and in managing care of buprenorphine patients

• Name issues in opioid recovery

Your registration includes continental breakfast and beverages. Time will be set aside for lunch which is available for purchase locally or you are most welcome to bring your own bag lunch.